JW Therapeutics, founded in 2016 by Juno Therapeutics and WuXi AppTec Group, is a Shanghai-based clinical-stage biopharmaceutical company focused on cell-based therapy technologies. The company has initiated development of its first CD19-directed investigational therapy, JWCAR029, a CAR-T being studied for B‑cell malignancies with an initial focus on relapsed and refractory DCBCL. JWCAR029 has moved into clinical phase and its IND was accepted by the China Food and Drug Administration (CFDA). JW Therapeutics has built a fully validated clinical GMP facility aligned with global QMS standards and assembled a leadership team of seasoned biotech/pharma executives led by CEO Hans Bishop. The company completed a $90M Series A financing and will use the proceeds to further advance the JWCAR029 clinical program and develop a broader therapeutic pipeline. JW Therapeutics also plans to build a new commercial manufacturing facility.

Total raised

$90M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2018